Guided by nature.
Realized through science.

Andrea Nye brings over 15 years of senior leadership experience to Xylyx Bio, with deep knowledge of the biotechnology entrepreneurship sector and the intersection of business, science, medicine, and government. She joined Xylyx from Columbia BiomedX, where as Managing Director she oversaw targeted investment aimed at vetting and supporting promising early-stage ventures bringing medical technology products to market. Andrea has consulted with multiple successfully early-stage start-ups to define clinical road maps and go-to-market strategies, compose business plans, and assess commercial products in terms of market opportunity. She holds an MBA and MPH from Columbia University.

Dr. John O’Neill is an expert in regenerative bioengineering. He has published extensively on novel ex vivo whole organ support systems for donor organ evaluation, rehabilitation, and transplantation, and on tissue-specific extracellular matrix (ECM) biomaterials for disease modeling, pharmaceutical drug testing, and therapeutic applications. He is an inventor of multiple pending and issued patents spanning diagnostic and therapeutic tools, devices, and technologies. Dr. O’Neill received a PhD in Biomedical Engineering from Columbia University and a BS in Physics and BA in Classical Language and Literature from the University of California at Santa Barbara. Prior to co-founding Xylyx Bio, he performed post-doctoral research in the Laboratory for Stem Cells and Tissue Engineering at Columbia University Medical Center.

Anthony Curro has over 35 years of senior executive experience in life sciences, technology, and finance, with demonstrated expertise in business strategy, market and risk assessment, global distribution, and the commercialization of novel biotechnologies. He served as Vice President and General Manager of Australia-based Compumedics, heading up their North American business unit, and as a Director at medical device powerhouse Guidant (Boston Scientific), where he successfully grew the company’s portfolio of cardiovascular products. He also served as CEO at Immplacate, a cell therapy company, and Spruce Technology, where he led the firm through an extended period of high growth and expansion. Tony holds an MBA from Columbia University, serves on multiple corporate boards, and has an established network that extends through the Americas, Europe, and the Pacific Rim.

Dr. Evelyn Aranda is an expert in developing models to recapitulate diseases such as cancer metastasis, with a focus on emerging tumor microenvironment, tumor development and progression, and liver and lung fibrosis pathogenesis, dysregulated metabolism, inflammation, and mechanisms of disease progression. Dr. Aranda earned her Ph.D. from the Physiology Department at Pontificia Universidad Católica de Chile and did postdoctoral training at Albert Einstein College of Medicine in New York.